Compare LYFT & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LYFT | ERAS |
|---|---|---|
| Founded | 2007 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 5.5B |
| IPO Year | 2019 | 2021 |
| Metric | LYFT | ERAS |
|---|---|---|
| Price | $13.73 | $10.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 29 | 12 |
| Target Price | ★ $20.07 | $14.25 |
| AVG Volume (30 Days) | ★ 13.1M | 9.3M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11250.00 | 36.23 |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $6,316,261,000.00 | N/A |
| Revenue This Year | $17.33 | N/A |
| Revenue Next Year | $12.29 | N/A |
| P/E Ratio | $346.63 | ★ N/A |
| Revenue Growth | ★ 9.16 | N/A |
| 52 Week Low | $12.46 | $1.06 |
| 52 Week High | $25.54 | $24.28 |
| Indicator | LYFT | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 43.32 | 36.76 |
| Support Level | $12.88 | $2.07 |
| Resistance Level | $14.24 | $16.14 |
| Average True Range (ATR) | 0.56 | 1.29 |
| MACD | -0.07 | -0.55 |
| Stochastic Oscillator | 22.01 | 11.04 |
Lyft is the second-largest ride-sharing service provider in the US and Canada, connecting riders and drivers over the Lyft app. Incorporated in 2013 and public since 2019, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.